Search

Anavex Life Sciences Corp

Închisă

SectorSănătate

1.55 -3.13

Rezumat

Modificarea prețului

24h

Curent

Minim

1.55

Maxim

1.7

Indicatori cheie

By Trading Economics

Venit

14M

7.8M

EPS

0.08

Angajați

34

EBITDA

3.3M

-3.2M

Dividende

By Acuity

Următoarele câștiguri

24 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-136M

152M

Deschiderea anterioară

4.68

Închiderea anterioară

1.55

Sentimentul știrilor

By Acuity

93%

7%

308 / 340 Clasament în Healthcare

Anavex Life Sciences Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 oct. 2026, 20:00 UTC

News

Anavex Life Sciences Corp shares fell sharply amid increased scrutiny from class action lawsuits alleging securities fraud related to the company's operations and internal controls.

5 oct. 2026, 20:01 UTC

News

Anavex Life Sciences Corp faces a class action lawsuit alleging false statements, contributing to a sharp decline in shares after an initial rise today.

2 oct. 2026, 19:35 UTC

News

Anavex Life Sciences Corp faces a class action lawsuit over alleged misconduct, contributing to a continued decline in shares amid negative sentiment.

1 oct. 2026, 20:06 UTC

News

Anavex Life Sciences Corp shares fell sharply amid multiple investigations and class action lawsuits related to alleged securities fraud and internal control weaknesses.

30 sept. 2026, 23:20 UTC

Anavex Life Sciences Corp is moving higher in after-market trading, reflecting a broader market advance following a revised Q2 GDP growth rate of 2.2%.

29 sept. 2026, 19:36 UTC

Anavex Life Sciences Corp shares are higher in the current session, gaining since Monday, though they remain below their 20-day moving average.

25 sept. 2026, 20:01 UTC

Anavex Life Sciences Corp is experiencing an upward movement, gaining ground since Thursday's close, though still below its 20-day moving average.

24 sept. 2026, 19:35 UTC

Anavex Life Sciences Corp is trading roughly flat, reflecting little change since Wednesday's close amid a broader market decline over the past month.

23 sept. 2026, 23:10 UTC

Anavex Life Sciences Corp is up in after-market trading, gaining ground since Wednesday's close despite remaining below its 20-day moving average.

16 sept. 2026, 19:46 UTC

Anavex Life Sciences Corp shares fell sharply, continuing an eight-session decline and reaching a new low, remaining well below the 20-day moving average.

15 sept. 2026, 20:03 UTC

News

Anavex Life Sciences Corp shares declined as PVG Asset Management criticized the board's governance, urging shareholders to support their nominees amid perceived failures.

10 sept. 2026, 20:07 UTC

News

Anavex Life Sciences shares are lower as PVG Asset Management plans a proxy campaign to change the board, citing concerns over governance and leadership.

9 sept. 2026, 19:46 UTC

News

Anavex Life Sciences shares decline as PVG Asset Management calls for a board replacement, citing concerns over inexperience and funding issues for upcoming trials.

8 sept. 2026, 20:21 UTC

Anavex Life Sciences Corp shares are lower in after-market trading, declining significantly below the 20-day moving average and near the lower end of its one-month range.

4 sept. 2026, 19:46 UTC

News

Anavex Life Sciences is rising as PVG Asset Management proposes changes to its Board of Directors, aiming to enhance governance and accountability.

3 sept. 2026, 19:46 UTC

News

Anavex Life Sciences has regained Nasdaq compliance but shares are lower. The stock remains below its 20-day moving average amid broader market sentiment.

2 sept. 2026, 21:01 UTC

News

Anavex Life Sciences regained compliance with Nasdaq rules after filing overdue reports. Shares are lower in after-market trading, reflecting broader market dynamics.

1 sept. 2026, 19:54 UTC

Anavex Life Sciences Corp shares are trading higher today, recovering from an early dip amid broader market pressures and rising Treasury yields.

31 aug. 2026, 21:01 UTC

Anavex Life Sciences Corp is trading higher in after-market hours, rebounding from earlier lows after five sessions of declines.

28 aug. 2026, 19:16 UTC

Anavex Life Sciences Corp. shares are lower today, extending a three-session decline amid broader market concerns over inflation and corporate growth expectations.

27 aug. 2026, 22:01 UTC

Anavex Life Sciences Corp is rising in after-hours trading, continuing a gradual ascent since Thursday's close, despite broader market conditions and no specific news.

26 aug. 2026, 23:41 UTC

Anavex Life Sciences Corp shares are higher during after-market hours, supported by a broader market trend. No specific company news was identified.

25 aug. 2026, 20:07 UTC

Event
News

Anavex Life Sciences reported Q3 2026 net income of $7.8 million, returning to profitability. Shares are trading higher following the financial results and pipeline updates.

24 aug. 2026, 23:11 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, building on positive momentum from Monday's close and a strong one-month performance.

21 aug. 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 aug. 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 aug. 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 aug. 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 aug. 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

13 aug. 2026, 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

Comparație

Modificare preț

Anavex Life Sciences Corp Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

308 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.